RPR Contract With Catalytica Gives Backup Synercid Production
Executive Summary
Rhone-Poulenc Rorer's licensing of Synercid production to Catalytica will provide the company with a backup facility for the production of the antibiotic.
You may also be interested in...
RPR To Pursue Synercid Pneumonia Indication With Early-2000 Submission
Rhone-Poulenc Rorer will submit results of a second hospital-acquired pneumonia study to FDA in early-2000 to broaden the indication for its injectable streptogramin antibiotic Synercid.
RPR To Pursue Synercid Pneumonia Indication With Early-2000 Submission
Rhone-Poulenc Rorer will submit results of a second hospital-acquired pneumonia study to FDA in early-2000 to broaden the indication for its injectable streptogramin antibiotic Synercid.
Rhone-Poulenc Rorer Targets September Launch For Synercid In U.K.
Rhone-Poulenc Rorer's injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin) is expected to be launched in the U.K. by October, following approval by the Medicines Control Agency on July 29.